These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 8108976)

  • 21. Does acute tubular necrosis affect renal transplant outcome? The impact of rejection episodes.
    Troppmann C; Almond PS; Payne WD; Dunn DL; Gores PF; Gruessner RW; Sutherland DE; Matas AJ; Najarian JS
    Transplant Proc; 1993 Feb; 25(1 Pt 2):905. PubMed ID: 8442263
    [No Abstract]   [Full Text] [Related]  

  • 22. The influence of cold ischemia and donor age on renal allograft outcome in the cyclosporine era.
    Cacciarelli TV; Sumrani N; DiBenedetto A; Hong JH; Sommer BG
    Transplant Proc; 1992 Oct; 24(5):2044-5. PubMed ID: 1412966
    [No Abstract]   [Full Text] [Related]  

  • 23. Evolution of immunosuppression in kidney transplantation: the Ohio State University experience.
    Rajab A; Pelletier RP; Henry ML; Elkhammas EA; Bumgardner GL; Davies EA; Orosz CG; Ferguson RM
    Clin Transpl; 2005; ():111-7. PubMed ID: 17424729
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early or delayed use of cyclosporine in HLA-mismatched living-related donor renal transplants.
    Sumrani N; Hong JH; Daskalakis P; Cacciarelli TV; Markell MS; Sommer BG
    Transplant Proc; 1993 Jun; 25(3):2246-7. PubMed ID: 8516888
    [No Abstract]   [Full Text] [Related]  

  • 25. Immunosuppressive regimens and their effects on renal allograft outcome.
    Katznelson S; Cecka JM
    Clin Transpl; 1996; ():361-71. PubMed ID: 9286582
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation.
    Opelz G; Döhler B;
    Transplantation; 2009 Mar; 87(6):795-802. PubMed ID: 19300179
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcome of kidney transplantation from non-heart-beating donors: comparison with heart-beating donors.
    Hattori R; Kinukawa T; Ohshima S; Matsuura O; Ono Y; Fujita T
    Transplant Proc; 1992 Aug; 24(4):1455-6. PubMed ID: 1496615
    [No Abstract]   [Full Text] [Related]  

  • 28. Outcome of cadaver kidneys using nonideal donors.
    Madden RL; Munda R; Hariharan S; Alexander JW; First MR
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1568-9. PubMed ID: 8442193
    [No Abstract]   [Full Text] [Related]  

  • 29. Annual trends and triple therapy--1991-2000.
    Nishikawa K; Terasaki PI
    Clin Transpl; 2001; ():247-69. PubMed ID: 12211788
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cessation of steroids in pediatric renal transplant recipients treated with cyclosporine, azathioprine, and prednisolone.
    Francis DM; Walker RG; Jones C; Powell H
    Transplant Proc; 1994 Feb; 26(1):99-101. PubMed ID: 8109043
    [No Abstract]   [Full Text] [Related]  

  • 31. Kidney transplantation, the Halifax experience.
    Belitsky P; MacDonald AS; Lawen J; McAlister V; Bitter-Suermann H; Kiberd B; West K; Sketris I
    Clin Transpl; 1996; ():231-40. PubMed ID: 9286572
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Renal transplantation in Singapore.
    Vathsala A; Woo KT; Rauff A; Lim CH
    Transplant Proc; 1992 Oct; 24(5):1819-20. PubMed ID: 1412863
    [No Abstract]   [Full Text] [Related]  

  • 33. Omit HLA matching to attain shorter cold ischemic time?
    Aswad S; Mann SL; Khetan U; Asai P; Bogaard T; Mendez RG; Mendez R
    Transplant Proc; 1993 Dec; 25(6):3053-5. PubMed ID: 8266450
    [No Abstract]   [Full Text] [Related]  

  • 34. Beneficial effects of prophylactic OKT3 in cadaver kidney transplantation: comparison with cyclosporin A in a single-center prospective randomized study.
    Goldman M; Abramowicz D; De Pauw L; Marécaux G; Vanderwinden JM; Kinnaert P; Vereerstraeten P
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1046-7. PubMed ID: 1899148
    [No Abstract]   [Full Text] [Related]  

  • 35. Sequential biological immunosuppression. Induction therapy with rabbit antithymocyte globulin.
    Guttmann RD; Flemming C
    Clin Transplant; 1997 Jun; 11(3):185-92. PubMed ID: 9193840
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evolution of immunosuppression at the University of Minnesota.
    Matas AJ; Sutherland DE; Najarian JS
    Transplant Proc; 2004 Mar; 36(2 Suppl):64S-70S. PubMed ID: 15041309
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of HLA matching on graft survival in live donor kidney transplantations.
    Velidedeoğlu E; Bilgin N; Haberal M
    Transplant Proc; 1993 Dec; 25(6):3144-5. PubMed ID: 8266491
    [No Abstract]   [Full Text] [Related]  

  • 38. Single-center analysis of 468 first cadaveric kidney allografts with a uniform ATG-CsA sequential therapy.
    Giral M; Taddei C; Nguyen JM; Dantal J; Hourmant M; Cantarovich D; Blancho G; Ancelet D; Soulillou JP
    Clin Transpl; 1996; ():257-64. PubMed ID: 9286575
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevention of rejection and graft loss with an aggressive quadruple immunosuppressive therapy regimen in children and adolescents.
    Conley SB; al-Uzri A; So S; Salvatierra O
    Transplantation; 1994 Feb; 57(4):540-4. PubMed ID: 8116038
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adverse effects of OKT3 therapy: increased risk with impaired renal function.
    Kehinde EO; Scriven SD; Feehally J; Veitch PS; Varty K; Bell PR
    Transplant Proc; 1994 Aug; 26(4):1945-7. PubMed ID: 8066629
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.